加载中
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
收盘时
US$3.72
−US$0.02 · -0.53%
盘后
US$3.72
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
日内区间
当前US$3.72
52周区间
当前US$3.72
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
60
合理估值
情绪
65
看涨
风险
52
风险偏高
动量
66
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
日内区间
当前US$3.72
52周区间
当前US$3.72
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.5亿 USD | 1.48亿 USD | 5719.3万 USD | 1.5亿 USD | 7564.3万 USD |
| 销货成本 | 4318.1万 USD | 1229.9万 USD | 822.2万 USD | 738.4万 USD | 265.1万 USD |
| 毛利 | 1.06亿 USD | 1.36亿 USD | 4897.1万 USD | 1.43亿 USD | 7299.2万 USD |
| 研究与开发 | 1.4亿 USD | 1.77亿 USD | 1.67亿 USD | 2.07亿 USD | 2.15亿 USD |
| 销售、一般及管理费用 | 3916万 USD | 7104.7万 USD | 5218.8万 USD | 5894.9万 USD | 6301.4万 USD |
| 营业费用 | 1.79亿 USD | 2.47亿 USD | 2.17亿 USD | 2.64亿 USD | 2.76亿 USD |
| 利息收入 | 340万 USD | 942.1万 USD | 968.6万 USD | 170万 USD | 68万 USD |
| 利息支出 | 850.8万 USD | 111.5万 USD | 143万 USD | — | — |
| 折旧和摊销 | 717.2万 USD | 754万 USD | 964.5万 USD | 1186.5万 USD | 1125.8万 USD |
| 营业利润 | −7284.1万 USD | −1.11亿 USD | −1.68亿 USD | −1.21亿 USD | −2.03亿 USD |
| 净利润 | −7462万 USD | −6696.6万 USD | −905.8万 USD | −1.2亿 USD | −2.02亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.00
上涨空间 61.29%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI768.28万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM591.61万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF265.95万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO191.14万0.01%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO144.36万0.01%180亿 USD0.06%US$112.27-0.35%
Fidelity Enhanced Small Cap ETFFESM118.93万0.02%64.1亿 USD0.28%US$45.24-0.48%
iShares Micro-Cap ETFIWC73.48万0.06%13.17亿 USD0.60%US$181.66-0.73%
ALPS Medical Breakthroughs ETFSBIO30.03万0.16%1.91亿 USD0.50%US$53.85-2.16%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
